Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Oleclumab by AstraZeneca for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Oleclumab by AstraZeneca for Prostate Cancer: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II...
Oleclumab by AstraZeneca for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Oleclumab by AstraZeneca for Solid Tumor: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Oleclumab by AstraZeneca for Osteosarcoma: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...
Oleclumab by AstraZeneca for Non-Small Cell Lung Cancer: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Oleclumab by AstraZeneca for Angiosarcoma: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II drugs...
Oleclumab by AstraZeneca for Dedifferentiated Liposarcoma: Likelihood of Approval
Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Oleclumab?
Oleclumab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According...